If you listen to Dyadic's most recent conference c
Post# of 30028
(Total Views: 451)
Posted On: 12/18/2021 7:47:11 PM
.jpg)
If you listen to Dyadic's most recent conference call, they talk about a newly formalized, but long in discussion collaboration with a Finnish entity and also previewed the Janssen agreement. The Finnish entity could be anything, but it's not a stretch to triangulate the Saarma network of folks who've been making exciting advancements in tech to get MANF-like CDNF across the BBB via nasal routes and new chemistry and continue to investigate MANF. Dyadics new Chief Business Officer is part of the Mike Rea network.
https://www2.helsinki.fi/en/researchgroups/ne...n/research
Could MANF be the C1 Target?
https://seekingalpha.com/pr/18605880-dyadic-a...facture-of
From the call:
"Mark Emalfarb
Yes, yes, we do. We actually -- in R&D, virtually every month or every 45 days, depending on the progress of projects, we have -- now, it's a Zoom meeting, but actually, run in for the first time since COVID was actually in Finland at VTT this week with one of our collaborators.
John Vandermosten
Okay, great. Great. And I guess how many active collaborators do you do estimate we have right now? I think I have a list of about 40 -- about 40 different entities that you work with? How many of those could we consider to be active?
Ping Rawson
Well, John, I think that's like Mark mentioned earlier, a lot of them, we can't really publicly talk about that. And there are a lot of ones that's -- the one that you have on the list are very accurate in terms of the ones that we have already announced.
Like this quarter, we actually signed additional two new collaborations, which we can only give you, you know, the general description of the organization. We can't really name them, but one of them is, you know, academia like a institution, which we have been in touch with them for a long time.
And the other one is industry partner that we are exploring potential opportunities to afford a different industry, And to be to kind of reinforce the statement that we made in prior calls, we do expect still to announce the human pharmaceutical collaboration between now and the end of the year with a big pharma company."
https://www2.helsinki.fi/en/researchgroups/ne...n/research
Could MANF be the C1 Target?
https://seekingalpha.com/pr/18605880-dyadic-a...facture-of
From the call:
"Mark Emalfarb
Yes, yes, we do. We actually -- in R&D, virtually every month or every 45 days, depending on the progress of projects, we have -- now, it's a Zoom meeting, but actually, run in for the first time since COVID was actually in Finland at VTT this week with one of our collaborators.
John Vandermosten
Okay, great. Great. And I guess how many active collaborators do you do estimate we have right now? I think I have a list of about 40 -- about 40 different entities that you work with? How many of those could we consider to be active?
Ping Rawson
Well, John, I think that's like Mark mentioned earlier, a lot of them, we can't really publicly talk about that. And there are a lot of ones that's -- the one that you have on the list are very accurate in terms of the ones that we have already announced.
Like this quarter, we actually signed additional two new collaborations, which we can only give you, you know, the general description of the organization. We can't really name them, but one of them is, you know, academia like a institution, which we have been in touch with them for a long time.
And the other one is industry partner that we are exploring potential opportunities to afford a different industry, And to be to kind of reinforce the statement that we made in prior calls, we do expect still to announce the human pharmaceutical collaboration between now and the end of the year with a big pharma company."
(1)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼